Search
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InhibitorsNoscapine
go.drugbank.com/drugs/DB06174ApprovedCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A InhibitorsRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesZosuquidar
go.drugbank.com/drugs/DB06191InvestigationalIts action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Categories: P-glycoprotein inhibitorsRufinamide
go.drugbank.com/drugs/DB06201ApprovedRufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2E1 InhibitorsTolvaptan
go.drugbank.com/drugs/DB06212ApprovedInvestigationalTolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsVadimezan
go.drugbank.com/drugs/DB06235InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnSitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown eff...
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the E...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, P-glycoprotein inhibitors